Navigation Links
Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
Date:2/26/2008

PRINCETON, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced the completion of recruitment in the company's multi-center Phase 2a clinical study of PS433540 (DARA), the company's lead internal product candidate. The objective of the Phase 2a randomized, double-blind, placebo-controlled, parallel-group study is to evaluate the efficacy and safety of 200 and 500 mg of PS433540 in subjects with Stage I and Stage II hypertension.

"We have made good progress advancing DARA's clinical development. Not only did we initiate this Phase 2a study approximately six months ahead of our original clinical development timeline, but we have now completed enrollment in the study with the expectation of reporting results in the second quarter of 2008," said Les Browne, Ph.D., Pharmacopeia's President and Chief Executive Officer. "As this is the first PS433540 study to include hypertensive patients, we are pleased to have the opportunity to demonstrate that DARA can effectively lower blood pressure in this patient population."

Results from Phase 1 studies of PS433540 in normal subjects have indicated that the compound was well tolerated at all doses up to and including 1,000 mg a day for 14 days. Several studies including the multiple ascending dose (MAD) and angiotensin II challenge studies have shown that PS433540 appears to have a pharmacokinetic profile consistent with once-daily oral administration. In the angiotensin challenge study, 250 and 500 mg of PS433540 fully blocked the increase in blood pressure induced by administration of angiotensin II (AII) to healthy volunteers at least as well as 300 mg of irbesartan, the t
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
3. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
4. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
5. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
6. Pharmacopeia Announces Third Quarter 2007 Financial Results
7. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
8. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
9. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... "Scintillator Market by Composition of Material, Application (Healthcare, ... others), End Product (Personal Instrument, Hand-Held Instruments, Fixed, ... and Analysis to 2013 - 2020", published by MarketsandMarkets, the ... CAGR of 5.62% from 2014 to 2020, and ...
(Date:7/11/2014)... -- Kindred Hospital Houston Northwest, with Wound Care Specialists, ... new outpatient wound healing center.  The wound healing ... hard to heal wounds. Chronic wounds include diabetic ... leg wounds related to blood flow issues, post-surgical ... wounds which are complex and demonstrate delayed healing. ...
(Date:7/11/2014)... On Thursday, July 10, 2014, the ... Industrial Average finished the day 0.42% lower at 16,915.07, and ... were broad based as eight out of ten sectors ended ... Index ended the day at 711.88, down 0.02%, while the ... has initiated coverage on the following equities: Covidien PLC (NYSE: ...
Breaking Medicine Technology:Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4
... 2011 Reportlinker.com announces that a new ... catalogue: Dental Implants and ... and Market Forecasts to 2016 ... Implants and Biomaterials - Global Pipeline Analysis, ...
... 2011 Reportlinker.com announces that a new market ... Hospital Mammography Census ... the most comprehensive European market report on the ... Mammography, R&F, Angiography, CT, MRI,) and radiology IT ...
Cached Medicine Technology:Reportlinker Adds Dental Implants and Biomaterials - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 2Reportlinker Adds Dental Implants and Biomaterials - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 3Reportlinker Adds Hospital Mammography Census 2
(Date:7/13/2014)... The report “Micronutrient Market by Type (Zinc, ... Non Chelated), Application Mode (Soil, Foliar, Fertigation), Crop ... to 2018” defines and segments the global agriculture ... the global value and volume for agriculture micronutrients. ... for the global agriculture micronutrients market with an ...
(Date:7/13/2014)... 13, 2014 MarketsandMarkets recently conducted ... Modeling; 3D Scanning; 3D rendering; Layout and Animation; ... (2013 - 2018)”, which analyzes and studies the ... America, Western Europe, Eastern Europe, Middle East and ... draws the competitive landscape of the 3D imaging ...
(Date:7/13/2014)... WA (PRWEB) July 13, 2014 Athletes ... longer recovery period from concussions, according to research presented ... ( AOSSM ) Annual Meeting. The research marks the ... concussion based on the known physical events that occur ... patients with a long allele in the (GT)n genotype ...
(Date:7/13/2014)... July 13, 2014 Recently, MyDressCity.com, one ... women’s special occasion outfits, has released its new range ... the new products are available at discounted prices. Worldwide ... 2014. , In the company’s online shop, there ... of them are made with great materials. MyDressCity.com’s hot ...
(Date:7/13/2014)... COPENHAGEN, July 13, 2014 A decreased ability ... cognitive impairment and Alzheimer,s disease, while examinations of ... a protein associated with Alzheimer,s, in the brain, ... reported today at the Alzheimer,s Association International Conference ... of the studies, the decreased ability to identify ...
Breaking Medicine News(10 mins):Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7
... KR ) said today,it is recalling Private Selection Peanut ... butter in the ice cream was supplied by,Peanut Corporation of ... following names are included in this recall: City Market, ... Stores the company operates under the following names ...
... factors are just as reliable, researchers say, , , MONDAY, ... variation is associated with an increased risk for heart ... who is likely to get heart disease any more ... , There has been continuing excitement in recent years ...
... early-stage lung cancer are not seen when patients are ... January issue of Archives of Surgery , one ... deaths in the United States than any other cancer, ... surgery to remove a portion of the lungprovides the ...
... received recommended care did better, regardless of race, study ... disparities between white and black patients with early-stage lung ... to a U.S. study that included nearly 18,000 patients. ... lung (pulmonary resection) provides the best chance of a ...
... of blood pressure, other factors may be boosting survival, ... First-time heart attacks in the United States aren,t as ... a long-running study finds. , "We know that deaths ... Meyerson, director of the cardiovascular disease prevention program at ...
... specializing in healthcare services at Affiliated Computer Services, Inc. ... highest ranking in a national survey for the second ... place award for its work in the Financial Enterprise ... Top 20 Best in KLAS Awards: Software & Professional ...
Cached Medicine News:Health News:Kroger Recalls Select Ice Cream Products Due to Possible Health Risk 2Health News:Genetic Data May Not Boost Heart Disease Predictions 2Health News:Study examines racial disparities in survival among patients diagnosed with lung cancer 2Health News:Optimal Treatment Boosts Blacks' Lung Cancer Survival 2Health News:U.S. Heart Attacks Becoming Less Severe 2Health News:U.S. Heart Attacks Becoming Less Severe 3Health News:ACS is 'Best in KLAS' for Healthcare Financial Implementation Services for Second Consecutive Year 2Health News:ACS is 'Best in KLAS' for Healthcare Financial Implementation Services for Second Consecutive Year 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: